Eric Benevich Sells 19,818 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now directly owns 40,778 shares in the company, valued at approximately $5,438,154.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00.

Neurocrine Biosciences Trading Down 0.5 %

Shares of NBIX opened at $132.54 on Friday. The firm has a market cap of $13.19 billion, a PE ratio of 54.77 and a beta of 0.25. The company’s 50 day simple moving average is $136.16 and its 200-day simple moving average is $126.85. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period last year, the firm posted $0.88 earnings per share. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on NBIX shares. JPMorgan Chase & Co. increased their price target on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. The Goldman Sachs Group increased their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Wedbush reissued an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday. Barclays raised their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Finally, Citigroup reduced their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $139.67.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently modified their holdings of NBIX. FCF Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $1,157,000. Redhawk Wealth Advisors Inc. acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $1,245,000. HealthInvest Partners AB acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $1,662,000. Nordea Investment Management AB raised its stake in shares of Neurocrine Biosciences by 205.7% during the 3rd quarter. Nordea Investment Management AB now owns 28,591 shares of the company’s stock worth $3,279,000 after buying an additional 19,238 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Neurocrine Biosciences by 28.3% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 69,596 shares of the company’s stock worth $9,138,000 after buying an additional 15,367 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.